Press release -
Athera reports last patient visit for Phase 2 trial in STEMI patients
Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic antibodies, announced that the last patient visit has been completed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure following an acute myocardial infarction. The study completed recruitment in March by including 82 patients with STEMI and aims for top-line results to be presented in 2020, in accordance with earlier plans.
The study is designed to evaluate if treatment with ATH3G10 significantly decreases the risk of heart failure following myocardial infarction in comparison to placebo. The study targeted inclusion of approximately 80 patients with acute myocardial infarction and high risk to develop heart failure. Treatment effect is measured by Magnetic Resonance Imaging (MRI) scans that correlate with development of heart failure. A total of 15 hospitals in Sweden, Denmark and The Netherlands participated in the study.
“We are so proud and grateful to be working with such an outstanding study organization. Despite huge challenges from the Coronavirus pandemic during recent months, the team’s efforts in patient follow-up have been outstanding. We have now received MRI scans from all planned follow-up patient visits, meaning that we have a good data set to evaluate the treatment effects,” says James Hall, CEO of Athera. “We owe the teams at the acute cardiology units and at the MRI units gratitude for their outstanding dedication and active conduct of the study. This has been one of the quickest trials to recruit in this patient population in recent years”.
The results will be evaluated after the database is locked and are planned to be communicated at a scientific congress later this year.
Topics
- Corporate Information
Categories
- hjärtinfarkt
- athera
- athera biotechnologies
- clinical study
- cardiovascular disease
- inflammation
- clinical
- läkemedel
- hjärtkärlsjukdom
- therapeutic antibody
About ATH3G10
ATH3G10 is a first-in-class fully human antibody to target phosphorylcholine (PC), the head group of oxidized phospholipids (oxPLs), an epitope on damaged or stressed cells. The candidate is initially being developed for patients with a large ST-elevation myocardial infarction (STEMI) who are at high risk of heart failure. Tissue from infarcted myocardium that has suffered an injury has large amounts of exposed PC, indicating that the body is not clearing away damaged cells effectively. Non-resolving inflammation can lead to cardiac remodelling and heart failure within months. The 5-year mortality in heart failure is 50%—worse than many cancers.
About Athera Biotechnologies AB
The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease. In addition to an intravenous formulation of ATH3G10 for use in acute settings, Athera is developing a subcutaneous version for longer-term, repeat dosing in different conditions. Major shareholders in Athera are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB. For more information: www.athera.se
